[8-K] HELIUS MEDICAL TECHNOLOGIES, INC. Reports Material Event
Solana Company furnished a press release under Item 7.01 (Regulation FD) on October 20, 2025. The release is attached as Exhibit 99.1 and incorporated by reference in this report.
The Item 7.01 information, including Exhibit 99.1, is furnished and not filed, is not subject to Section 18 of the Exchange Act, and will not be incorporated into Securities Act or Exchange Act filings except by specific reference. Solana Company was formerly known as Helius Medical Technologies, Inc., and its Class A Common Stock trades on Nasdaq under HSDT.
Solana Company ha emesso un comunicato stampa ai sensi della Regola 7.01 (Regulation FD) il 20 ottobre 2025. Il comunicato è allegato come Allegato 99.1 e richiamato a riferimento in questo rapporto.
Le informazioni di Item 7.01, compreso l'Allegato 99.1, sono fornite e non depositate, non soggette alla Sezione 18 del Securities Exchange Act, e non saranno incorporate nei filing del Securities Act o dell Exchange Act salvo per esplicita rinuncia. Solana Company era precedentemente nota come Helius Medical Technologies, Inc., e il suo azioni ordinarie di Classe A sono negoziate sul Nasdaq con ticker HSDT.
Solana Company publicó un comunicado de prensa conforme al Artículo 7.01 (Regulación FD) el 20 de octubre de 2025. El comunicado se adjunta como Exhibit 99.1 e incorporado por referencia en este informe.
La información del Artículo 7.01, incluyendo el Exhibit 99.1, se proporciona y no se presenta, no está sujeta a la Sección 18 de la Ley de Valores y, a menos que se haga referencia específica, no se incorporará a presentaciones de la Securities Act o de la Exchange Act. Solana Company solía llamarse Helius Medical Technologies, Inc., y sus acciones ordinarias de Clase A cotizan en Nasdaq bajo HSDT.
Solana Company는 2025년 10월 20일 제7.01항( Regulation FD)에 따른 보도자료를 공표했다. 해당 보도자료는 Exhibit 99.1로 첨부되며 이 보고서에 참고로 포함된다.
제7.01항 정보는 Exhibit 99.1을 포함하며 공시되어 있으며, 제출되지 않으며, Exchange Act의 18조에 따라야 할 의무가 없고, Securities Act 또는 Exchange Act의 filings에 특별한 참조 없이는 포함되지 않을 것이다. Solana Company는 이전에 Helius Medical Technologies, Inc.로 알려졌으며, 그 Class A 보통주는 Nasdaq에서 HSDT로 거래된다.
Solana Company a publié un communiqué de presse conformément à l'article 7.01 (Regulation FD) le 20 octobre 2025. Le communiqué est joint en tant que Exhibit 99.1 et est incorporé par référence dans ce rapport.
Les informations de l'article 7.01, y compris l'Exhibit 99.1, sont fournies et non déposées, ne sont pas soumises à la Section 18 du Securities Exchange Act et ne seront pas intégrées dans les dépôts du Securities Act ou du Exchange Act sauf référence spécifique. Solana Company était auparavant connue sous le nom de Helius Medical Technologies, Inc., et ses actions ordinaires de classe A se négocient sur le Nasdaq sous le symbole HSDT.
Solana Company hat am 20. Oktober 2025 eine Pressemitteilung im Rahmen von Punkt 7.01 (Regulation FD) veröffentlicht. Die Mitteilung ist als Exhibit 99.1 beigefügt und in diesen Bericht aufgenommen.
Die Informationen gemäß Item 7.01, einschließlich Exhibit 99.1, werden bereitgestellt und nicht eingereicht, unterliegen nicht Section 18 des Securities Exchange Act und werden nicht in Securities Act- oder Exchange Act-Einreichungen aufgenommen, außer durch ausdrückliche Bezugnahme. Solana Company war früher unter dem Namen Helius Medical Technologies, Inc. bekannt, und ihre Class A Stammaktien werden an der Nasdaq unter dem Ticker HSDT gehandelt.
Solana Company أصدرت بياناً صحافياً بموجب البند 7.01 (Regulation FD) في 20 أكتوبر 2025. يتم إرفاق البيان كالمرفق Exhibit 99.1 ودمجه بالإشارة في هذا التقرير.
يتم تقديم معلومات البند 7.01، بما في ذلك Exhibit 99.1، وليست مُقدمة كوثائق مودعة، وليست خاضعة للمادة 18 من قانون الأوراق المالية والتبادل، ولن يتم إدراجها في ملفات Securities Act أو Exchange Act إلا بالإشارة المحددة. كانت Solana Company تعرف سابقاً باسم Helius Medical Technologies, Inc.، وتداول أسهمها العادية من فئة A في Nasdaq تحت الرمز HSDT.
Solana Company 于 2025 年 10 月 20 日发布了符合第 7.01 条款（Regulation FD）的新闻稿。该新闻稿作为 Exhibit 99.1 附件提供，并在本报告中通过引用并入。
第 7.01 条信息，包括 Exhibit 99.1，被提供而非备案，不受美国证券交易法第 18 条的约束，除非特别引用，否则不会并入证券法或交易法的披露。Solana Company 以前被称为 Helius Medical Technologies, Inc.，其 A 类普通股在纳斯达克以 HSDT 交易。
- None.
- None.
Solana Company ha emesso un comunicato stampa ai sensi della Regola 7.01 (Regulation FD) il 20 ottobre 2025. Il comunicato è allegato come Allegato 99.1 e richiamato a riferimento in questo rapporto.
Le informazioni di Item 7.01, compreso l'Allegato 99.1, sono fornite e non depositate, non soggette alla Sezione 18 del Securities Exchange Act, e non saranno incorporate nei filing del Securities Act o dell Exchange Act salvo per esplicita rinuncia. Solana Company era precedentemente nota come Helius Medical Technologies, Inc., e il suo azioni ordinarie di Classe A sono negoziate sul Nasdaq con ticker HSDT.
Solana Company publicó un comunicado de prensa conforme al Artículo 7.01 (Regulación FD) el 20 de octubre de 2025. El comunicado se adjunta como Exhibit 99.1 e incorporado por referencia en este informe.
La información del Artículo 7.01, incluyendo el Exhibit 99.1, se proporciona y no se presenta, no está sujeta a la Sección 18 de la Ley de Valores y, a menos que se haga referencia específica, no se incorporará a presentaciones de la Securities Act o de la Exchange Act. Solana Company solía llamarse Helius Medical Technologies, Inc., y sus acciones ordinarias de Clase A cotizan en Nasdaq bajo HSDT.
Solana Company는 2025년 10월 20일 제7.01항( Regulation FD)에 따른 보도자료를 공표했다. 해당 보도자료는 Exhibit 99.1로 첨부되며 이 보고서에 참고로 포함된다.
제7.01항 정보는 Exhibit 99.1을 포함하며 공시되어 있으며, 제출되지 않으며, Exchange Act의 18조에 따라야 할 의무가 없고, Securities Act 또는 Exchange Act의 filings에 특별한 참조 없이는 포함되지 않을 것이다. Solana Company는 이전에 Helius Medical Technologies, Inc.로 알려졌으며, 그 Class A 보통주는 Nasdaq에서 HSDT로 거래된다.
Solana Company a publié un communiqué de presse conformément à l'article 7.01 (Regulation FD) le 20 octobre 2025. Le communiqué est joint en tant que Exhibit 99.1 et est incorporé par référence dans ce rapport.
Les informations de l'article 7.01, y compris l'Exhibit 99.1, sont fournies et non déposées, ne sont pas soumises à la Section 18 du Securities Exchange Act et ne seront pas intégrées dans les dépôts du Securities Act ou du Exchange Act sauf référence spécifique. Solana Company était auparavant connue sous le nom de Helius Medical Technologies, Inc., et ses actions ordinaires de classe A se négocient sur le Nasdaq sous le symbole HSDT.
Solana Company hat am 20. Oktober 2025 eine Pressemitteilung im Rahmen von Punkt 7.01 (Regulation FD) veröffentlicht. Die Mitteilung ist als Exhibit 99.1 beigefügt und in diesen Bericht aufgenommen.
Die Informationen gemäß Item 7.01, einschließlich Exhibit 99.1, werden bereitgestellt und nicht eingereicht, unterliegen nicht Section 18 des Securities Exchange Act und werden nicht in Securities Act- oder Exchange Act-Einreichungen aufgenommen, außer durch ausdrückliche Bezugnahme. Solana Company war früher unter dem Namen Helius Medical Technologies, Inc. bekannt, und ihre Class A Stammaktien werden an der Nasdaq unter dem Ticker HSDT gehandelt.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| ||
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: (
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01Regulation FD Disclosure.
On October 20, 2025, Solana Company (formerly known as Helius Medical Technologies, Inc.) (the “Company”) issued a press release. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this report, and the inclusion of such website addresses in this report by incorporation by reference of the press release is as inactive textual references only.
Exhibit 99.1 hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.
The information in this report, including Exhibit 99.1 hereto, is furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company’s submission of this report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit No. |
| Description |
99.1 | Press Release, dated October 20, 2025. | |
104 | Cover Page Interactive Data File (embedded within Inline XBRL document). |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SOLANA COMPANY. | ||
|
|
|
|
Dated: October 20, 2025 |
| By: | /s/ Joseph Chee |
|
|
| Joseph Chee |
|
|
| Executive Chairman |
3
FAQ
What did Solana Company (HSDT) announce in its 8-K?
Is the Solana Company (HSDT) press release considered filed with the SEC?
Where can I find the Solana Company press release linked to this 8-K?
What is Solana Company's current trading symbol and exchange?
Does the 8-K incorporate the press release into other SEC filings?
What was Solana Company's former name?
